Skip to main content
Oxford University Press - PMC COVID-19 Collection logoLink to Oxford University Press - PMC COVID-19 Collection
. 2022 Jun 20:ciac501. doi: 10.1093/cid/ciac501

Hospitalized patients with severe COVID-19 during the Omicron wave in Israel – benefits of a fourth vaccine dose

Tal Brosh-Nissimov 1,2,, Khetam Hussein 3,4, Yonit Wiener-Well 5,6, Efrat Orenbuch-Harroch 7,8, Meital Elbaz 9,10, Shelly Lipman-Arens 11,12, Yasmin Maor 13,14, Yael Yagel 15,16, Bibiana Chazan 17,18, Mirit Hershman-Sarafov 19,20, Galia Rahav 21,22, Oren Zimhony 23,24, Adi Zaidman Shimshovitz 25,26, Michal Chowers 27,28
PMCID: PMC9278185  PMID: 35724127

Abstract

Background

Waning vaccine-immunity and an increased incidence of COVID-19 during the Omicron outbreak led the Israeli Ministry of Health to recommend a fourth dose of BNT162b2 for high-risk individuals. This study assessed the effect of that dose for hospitalized patients with severe/critical, breakthrough COVID-19.

Methods

In this multi-center retrospective cohort study of hospitalized adults with severe/critical COVID-19 in Israel, from 01/15/2022–01/31/2022, cases were divided according to the number of vaccinations received. Poor outcome was defined as mechanical ventilation or in-hospital death, and was compared between 3- and 4-dose vaccinees using logistic regression.

Results

Included were 1,049 patients, median age 80 years (IQR 69-87), 51% males. Among them, 394 were unvaccinated, 386 had received 3 doses and 88 4 doses. The 3-dose group was older, had more males and immunosuppression, but with similar outcomes, 49% vs. 51% compared to unvaccinated patients (p = 0.72). Patients after 4 doses were similarly older and immunosuppressed, but had better outcomes compared to unvaccinated patients, 34% vs. 51% (p < 0.01). We examined independent predictors for poor outcome in patients with either 3 or 4 doses, received a median of 161 (IQR 147-168) or 14 (IQR 10-18) days before diagnosis, respectively. Receipt of the fourth dose was associated with protection: OR 0.51 (95%CI 0.3-0.87), as was Remdesivir OR 0.65 (95%CI 0.44-0.96). Male sex, chronic renal failure and dementia were associated with poor outcomes.

Conclusions

Among hospitalized patients with severe/critical breakthrough COVID-19, a recent fourth dose was associated with significant protection against mechanical ventilation or death, compared to three doses.

Keywords: COVID-19, BNT162b2, vaccine, booster, fourth dose

Contributor Information

Tal Brosh-Nissimov, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba, Israel; Infectious Diseases Unit, Samson Assuta-Ashdod University Hospital, Ashdod, Israel.

Khetam Hussein, Rambam Health Care Campus, Haifa, Israel; Rappaport Faculty of Medicine, The Technion-Israel Institute of Technology, Haifa, Israel.

Yonit Wiener-Well, Shaare Zedek Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Efrat Orenbuch-Harroch, Division of Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Meital Elbaz, Department of Infectious Diseases, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Shelly Lipman-Arens, Rappaport Faculty of Medicine, The Technion-Israel Institute of Technology, Haifa, Israel; Infectious disease and Infection Control Unit, Hillel Yaffe Medical Center, Hadera, Israel.

Yasmin Maor, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Infectious Disease Unit, Wolfson Medical Center, Holon, Israel.

Yael Yagel, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheba, Israel; Infectious Disease Institute, Soroka Medical Center, Beer Sheba, Israel.

Bibiana Chazan, Rappaport Faculty of Medicine, The Technion-Israel Institute of Technology, Haifa, Israel; Infectious Diseases Unit, Emek Medical Center, Afula, Israel.

Mirit Hershman-Sarafov, Rappaport Faculty of Medicine, The Technion-Israel Institute of Technology, Haifa, Israel; Bnai Zion Medical Center, Haifa, Israel.

Galia Rahav, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel.

Oren Zimhony, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Infectious Diseases Unit, Kaplan Medical Center, Rehovot, Israel.

Adi Zaidman Shimshovitz, Rappaport Faculty of Medicine, The Technion-Israel Institute of Technology, Haifa, Israel; Infectious Disease Unit, The Baruch Padeh Medical Center, Tiberias, Israel.

Michal Chowers, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Meir Medical Center, Kfar Saba, Israel.

Supplementary Material

ciac501_Supplementary_Data

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ciac501_Supplementary_Data

Articles from Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America are provided here courtesy of Oxford University Press

RESOURCES